full list rate price target
earn chang report pleas see
tabl page
reason ow post deal
 implic gener
revisit myl-pf deal deriv increas confid invest thesi
initi sector ow gener
segment fortuna velut luna initi specialti posit
thesi base compani divers geograph footprint extens biosimilar
portfolio rel better qualiti gx portfolio believ deal reaffirm
framework strengthen myl fundament
reason deal benefit reiter ow de-risk
 gx enhanc global growth profil newco exposur
still challeng gx market vs current favor balanc growth
exposur would strengthen newco balanc sheet
improv target net leverag ye newco would stand
apart peer leverag pretti materi lever among
 gx coverag manag guid
vs legal risk better absorb
cautiou twin legal risk face gx sector price fix opioid
risk shift newco believ would much better posit financi
deal advers legal outcom
newco vs valuat upsid potenti rang multipl valu
stand-alon basi ntm ev/ebitda pt prior
result trade ebitda believ could form
floor multipl newco think would fundament stronger
improv leverag cash flow growth corpor govern myl long stand
govern concern like diminish announc manag chang
appli ev/ebitda rang reach hypothet valuat
rang base ownership newco pro forma
implic gener larg cap pharma deal provid blueprint
initi discuss consolid inevit within gx space combat
industri pressur howev balanc sheet gx compani stretch
 within industri seem less like propos myl-pf look like
innov deal within larg cap pharma could blueprint gx compani
acquir scale stabil requir counter advers industri develop
risk delay grestasi disappoint commerci progress worsen gx
environ potenti legal hurdl upjohn deal fall
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
merger pfizer upjohn busi creat stronger entiti
plan merg pfe upjohn unit off-pat brand gx medicin
busi pfizer upjohn unit carri icon brand mostli lost exclus statu
includ lyrica lipitor viagra believ new entiti transit
pfe current steril inject biosimilar busi innov medicin
busi view would ice cake note
potenti transit epipen manufactur unit spin-off
deal add scale
manag believ new busi larger global scale geograph
reach well differenti product portfolio pipelin expect pro forma sale
ebitda newli form compani
new compani expect
rev
ebitda
rev ebitda newco
compani data
myl exposur asia pacif increas nearli revenu china
today point key item strateg rational
deal highlight manag
combin add signific
exposur asia pacif
notabl china market
pro forma revenu mix geographi
furthermor combin entiti estim revenu exposur gx
 compar myl current exposur approxim half revenu
 view anoth key diversif benefit result merger
combin
upjohn expect diversifi
away gx
pro forma revenu mix product
see attract hypothet newco valuat support ow
valu stand-alon basi deal close ntm ev/ebitda multipl
pt trade ebitda believ could
form floor multipl newco believ would fundament stronger
improv leverag cash flow growth corpor govern myl long stand
govern concern partial address announc manag chang
appli ev/ebitda rang reach hypothet valuat rang
base ownership newco see figur
yield rang
declin y/i
world-wide basi
analys pfe upjohn iqvia data follow section highlight key trend
amongst largest product total upjohn product sale declin y/i
world-wide basi note gener version lyrica approv
anupjohnnewco total equiti ownership equiti dil valu per barclay specialti pharmaceut
gener version lyrica
approv launch
compani data figur
iqvia trend analysi top upjohn product
provid intern trend upjohn top product importantli
mani product off-pat sale level growth rate remain
term product overlap note sell atorvastatin glipitor pregabalin
glyrica sildenafil gviagra amlodipin gnorvasc
lyrica ww sale gx launch juli
changeworldwideunit lyrica salesy/i lipitor salesy/i growth barclay specialti pharmaceut
norvasc salesy/i celebrex salesy/i viagra salesy/i effexor salesy/i zoloft salesy/i growth barclay specialti pharmaceut
sale
ebitda
total debt close net leverag anticip
sharehold newco sharehold own
anticip close sharehold vote requir sharehold vote
requir
new ceo michael goettler current head pfe upjohn rajiv malik remain
presid robert couri execut chairman current ceo heather
bresch cfo ken park depart compani initi new cfo search
free cash flow paid dividend begin first full quarter close
deal term upjohn combin revers morri trust transact expect taxfre sharehold sharehold vote requir sharehold vote requir transact subject customari close condit includ receipt regulatori approv current expect close mid sharehold combin compani sharehold combin companycapit polici newco lower leverag ratio stand-alone total debt includ gross debt upjohn fund preclos cash payment solid invest grade credit rate stabl posit outlook expect compani pay dividend target pay-out free cash flowscorpor organ new manag robert couri execut chairman michael goettler ceo rajiv malik presid new board director chairman ceo appointe appointe newco domicil us incorpor delawar newco three global center pittsburgh shanghai hyderabad combin board fulli declassifi annual meet barclay specialti pharmaceut
sale profit beat consensu driven na product launch
report total sale vs consensu ep vs
consensu outlin segment result
na segment sale ahead consensu estim deliv
growth na segment driven new product launch fulphila wixela
off-set lower price volum within base busi
eu segment sale flat y/i slightli forecast consensu
cite strength new product sale hulio bhumira recent acquir tobi
row segment revenu increas y/i slightli ahead expect
volum china new product sale australia emerg market off-set
aforement fx headwind well lower price
new product launch na
manag reiter
ep
barclay research estim compani data refinitiv data except ep
full year sale ep guidanc reiter
barclay research estim compani data except ep
tweak estim pt
updat estim slightli incorpor result estim
prior ep prior primarili due lower opex
spend highlight chang previou estim figur
result pt move still base ntm ev/ebitda
slightli increas
ep due lower spend
barclay research estim compani data except ep
overweight ow base
extens biosimilar portfolio partnership
biocon think give edg truli
diversifi global segment complex gener
strong uptak wixela yupelri gcopaxon
delay grestasi disappoint commerci
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
valuat methodolog risk
valuat methodolog pt base ntm ev/ebitda multipl
risk may imped achiev barclay research valuat price downsid risk ow thesi includ
delay grestasi disappoint commerci progress worsen gener environ legal risk materi
balaji prasad md herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
